BLI Banque de Luxembourg Investments Invests $2.20 Million in Amgen Inc. (NASDAQ:AMGN)

BLI Banque de Luxembourg Investments bought a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 8,483 shares of the medical research company's stock, valued at approximately $2,200,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Beck Mack & Oliver LLC lifted its position in Amgen by 0.7% during the fourth quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company's stock valued at $1,205,000 after acquiring an additional 34 shares during the last quarter. Blossom Wealth Management raised its stake in Amgen by 3.5% in the fourth quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company's stock valued at $284,000 after buying an additional 37 shares during the last quarter. Zullo Investment Group Inc. boosted its holdings in Amgen by 2.8% in the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock worth $356,000 after acquiring an additional 37 shares in the last quarter. Trillium Asset Management LLC boosted its stake in Amgen by 4.2% in the 4th quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock worth $237,000 after purchasing an additional 37 shares in the last quarter. Finally, Evermay Wealth Management LLC increased its stake in Amgen by 1.5% during the 4th quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company's stock valued at $691,000 after purchasing an additional 38 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Amgen Stock Up 2.0 %

Amgen stock traded up $5.40 during trading on Wednesday, reaching $275.84. The stock had a trading volume of 2,363,022 shares, compared to its average volume of 2,761,448. The stock has a market cap of $148.31 billion, a PE ratio of 36.54, a P/E/G ratio of 2.63 and a beta of 0.51. The business has a 50 day moving average price of $297.78 and a 200 day moving average price of $290.54. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm had revenue of $8.15 billion during the quarter, compared to analysts' expectations of $8.05 billion. During the same quarter in the previous year, the business earned $3.96 earnings per share. The firm's revenue was up 9.4% compared to the same quarter last year. On average, analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.45%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio is currently 86.86%.

Insider Activity at Amgen

In related news, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the transaction, the executive vice president now directly owns 44,186 shares of the company's stock, valued at approximately $13,025,590.94. The trade was a 16.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the company's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 67,752 shares of company stock worth $20,160,532 in the last quarter. Company insiders own 0.69% of the company's stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research analyst reports. Mizuho boosted their price objective on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a report on Wednesday. Bank of America increased their price objective on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a report on Wednesday, March 5th. StockNews.com upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a report on Friday, May 2nd. Cantor Fitzgerald began coverage on shares of Amgen in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 price objective for the company. Finally, Truist Financial reduced their target price on shares of Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a report on Wednesday, January 8th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Amgen currently has a consensus rating of "Hold" and a consensus target price of $310.23.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.